tiprankstipranks
MEI Pharma Announces Executive Changes and Strategic Overhaul
Company Announcements

MEI Pharma Announces Executive Changes and Strategic Overhaul

Pick the best stocks and maximize your portfolio:

MEI Pharma (MEIP) has issued an announcement.

MEI Pharma, Inc. is exploring strategic alternatives to enhance shareholder value, which may include a sale or an orderly wind-down. As part of cost-saving measures, the company will start laying off employees and discontinue the clinical development of a drug candidate, voruciclib, while still pursuing some non-clinical activities. President and CEO David M. Urso and Chief Medical Officer Richard G. Ghalie are set to leave, with severance agreements in place, and the Board has appointed Justin J. File as Acting CEO. This shake-up, including a board chairperson change, is part of MEI Pharma’s significant strategic and operational restructuring.

For detailed information about MEIP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMEI Pharma Reports Strategic Shift Amid Financial Losses
TheFlyMEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App